UPDATE: Heron Therapeutics Q3 Adj. EPS $(0.04) Misses $(0.01) Estimate, Sales $38.213M Miss $39.031M Estimate
Benzinga Newsdesk 1 year ago
EarningsEarnings MissesNews
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.01) by 166.67 percent. This is a 33.33 percent decrease over losses of $(0.03) per share
Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.01) by 166.67 percent. This is a 33.33 percent decrease over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $38.213 million which missed the analyst consensus estimate of $39.031 million by 2.10 percent. This is a 16.47 percent increase over sales of $32.810 million the same period last year.